BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 2571333)

  • 1. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
    Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
    Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes.
    Bouchelouche P; Friche E; Sehested M; Jensen PB; Skovsgaard T
    Biochem Pharmacol; 1991 Jan; 41(2):243-53. PubMed ID: 1899193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation.
    Nielsen D; Maare C; Eriksen J; Litman T; Skovsgaard T
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1050-7. PubMed ID: 11704330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.
    Sehested M; Skovsgaard T; Jensen PB; Demant EJ; Friche E; Bindslev N
    Br J Cancer; 1990 Jul; 62(1):37-41. PubMed ID: 1975202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
    Friche E; Demant EJ; Sehested M; Nissen NI
    Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators.
    Sehested M; Jensen PB; Skovsgaard T; Bindslev N; Demant EJ; Friche E; Vindeløv L
    Br J Cancer; 1989 Dec; 60(6):809-14. PubMed ID: 2605092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1995 Aug; 50(4):443-50. PubMed ID: 7646548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
    Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
    Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
    Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of VP-16 to the classical multidrug resistance phenotype.
    Sehested M; Friche E; Jensen PB; Demant EJ
    Cancer Res; 1992 May; 52(10):2874-9. PubMed ID: 1581902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
    Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
    Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
    Friche E; Danks MK; Beck WT
    Cancer Res; 1992 Oct; 52(20):5701-6. PubMed ID: 1356619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells.
    Demant EJ; Sehested M; Jensen PB
    Biochim Biophys Acta; 1990 Nov; 1055(2):117-25. PubMed ID: 2242381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
    Friche E; Jensen PB; Nissen NI
    Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.
    Broxterman HJ; Kuiper CM; Schuurhuis GJ; Tsuruo T; Pinedo HM; Lankelma J
    Biochem Pharmacol; 1988 Jun; 37(12):2389-93. PubMed ID: 2898943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells.
    Sehested M; Skovsgaard T; Roed H
    Biochem Pharmacol; 1988 Sep; 37(17):3305-10. PubMed ID: 3401258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone.
    Nielsen D; Eriksen J; Maare C; Litman T; Kjaersgaard E; Plesner T; Friche E; Skovsgaard T
    Biochem Pharmacol; 2000 Aug; 60(3):363-70. PubMed ID: 10856431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin.
    Nielsen D; Eriksen J; Maare C; Jakobsen AH; Skovsgaard T
    Br J Cancer; 1998 Nov; 78(9):1175-80. PubMed ID: 9820176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance.
    Broxterman HJ; Pinedo HM; Kuiper CM; van der Hoeven JJ; de Lange P; Quak JJ; Scheper RJ; Keizer HG; Schuurhuis GJ; Lankelma J
    Int J Cancer; 1989 Feb; 43(2):340-3. PubMed ID: 2563722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.